Pfizer is on tap to present data for its vaccine Prevnar 13 from the CAPiTA trial at the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) on March 12. In a press release issued Feb. 24, the company said that the pneumonia vaccine worked against a first episode of vaccine-type community-acquired pneumonia in patients 65 and older in the study.

Read More…